CNS Drugs

, Volume 14, Issue 2, pp 81–94 | Cite as

Is Lithium Still the Maintenance Treatment of Choice for Bipolar Disorder?

  • Trevor Silverstone
Current Opinion


For over 25 years lithium was regarded as the drug of choice for prophylactic treatment in patients with bipolar disorder. More recently its place in the long term management of this condition has been questioned. A number of long term naturalistic studies have revealed that lithium is less effective in clinical practice than would be anticipated from clinical trial data. A major factor contributing to this discrepancy is the poor adherence to medication shown by over a third of patients taking the drug long term. Another possible reason is a broadening of the diagnostic criteria for bipolar disorder to include patients with mood-incongruent psychotic symptoms and/or comorbid substance abuse.

Following initially favourable reports from open studies, the anticonvulsant compounds carbamazepine and valproic acid (sodium valproate) have come to be widely used in the long term management of bipolar disorder. However, there is, thus far, little confirmatory evidence from controlled clinical trials to support this practice. The same is true for the use of the newer atypical antipsychotics and the newer anticonvulsants in the treatment of bipolar disorder. Until there is convincing evidence from controlled clinical trials that these alternatives are superior to lithium in improving the overall well-being of patients with bipolar disorder, it is my opinion that lithium remains the drug of choice.


Lithium Bipolar Disorder Carbamazepine Clozapine Risperidone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Yeragani VK, Gershon S. Hammond and lithium; historical update. Biol Psychiatry 1986; 21: 1101–2PubMedCrossRefGoogle Scholar
  2. 2.
    Schioldann J. John Cade’s seminal lithium paper turns fifty [editorial]. Acta Psychiatr Scand 1999; 100(6): 403–5PubMedCrossRefGoogle Scholar
  3. 3.
    Cade JFL. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 14: 349–52Google Scholar
  4. 4.
    Schou M, Juel-Nielson N, Stromgren E, et al. The treatment of manic psychoses by administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250–60PubMedCrossRefGoogle Scholar
  5. 5.
    Schou M. Lithium in psychiatric therapy: stock-taking after ten years. Psychopharmacologia 1959; 1: 65–78PubMedCrossRefGoogle Scholar
  6. 6.
    Goodwin FK, Jamison KR. Manic-depressive illness. 1st ed. New York (NY): Oxford University Press, 1990Google Scholar
  7. 7.
    The Expert Consensus Guideline Series. Treatment of bipolar disorder. J Clin Psychiatry 1996; 57 Suppl. 12A: 1–80Google Scholar
  8. 8.
    Bauer MS, Callahan AM, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs [see comments; published erratum appears in J Clin Psychiatry 1999; 60(5): 341]. J Clin Psychiatry 1999; 60(1): 9–21PubMedCrossRefGoogle Scholar
  9. 9.
    Bates B. Lithium is still top mood stabiliser for manic phase. Clin Psychiatry News 2000: 6Google Scholar
  10. 10.
    Hartigan GP. The use of lithium salts in affective disorders. Br J Psychiatry 1963; 109: 810–4PubMedCrossRefGoogle Scholar
  11. 11.
    Goodwin FK, Murphy DL, Bunney WF. Lithium carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Psychiatry 1969; 21: 486–96PubMedCrossRefGoogle Scholar
  12. 12.
    Corcoran AC, Taylor RD, Page IH. Lithium poisoning from the use of salt substitutes. J Am Med Assoc 1949; 139: 685–90PubMedCrossRefGoogle Scholar
  13. 13.
    Noack SH, Trautner EM. The lithium treatment of maniacal psychosis. Med J Aust 1951; 2: 219–22PubMedGoogle Scholar
  14. 14.
    Baastrup PC, Schou N. Lithium as a prophylactic agent: its effect against recurrent depression and manic depressive psychosis. Arch Gen Psychiatry 1967; 16: 162–72PubMedCrossRefGoogle Scholar
  15. 15.
    Blackwell B, Shepherd M. Prophylactic lithium: another therapeutic myth? Lancet 1968; I: 968–71CrossRefGoogle Scholar
  16. 16.
    Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet 1970; II: 326–30CrossRefGoogle Scholar
  17. 17.
    Coppen A, Noguera R, Bailey J. Prophylactic lithium in affectivedisorders. Lancet 1971; II: 275–9CrossRefGoogle Scholar
  18. 18.
    Prien R, Caffey E, Klett J. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973; 28: 337–41PubMedCrossRefGoogle Scholar
  19. 19.
    Davis JM, Janicak PG, Hogan DM. Mood stabilisers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100: 406–17PubMedCrossRefGoogle Scholar
  20. 20.
    Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am J Psychiatry 1994; 151(12 Suppl. ): 1–36Google Scholar
  21. 21.
    Harrow M, Goldberg JF, Grossman LS, et al. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47: 665–71PubMedCrossRefGoogle Scholar
  22. 22.
    Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilising survival analysis. Arch Gen Psychiatry 1990; 47: 1106–11PubMedCrossRefGoogle Scholar
  23. 23.
    Winokur G, Coryell W, Keller M, et al. A prospective follow-up of patients with bipolar and primary unipolar affective disorder. Arch Gen Psychiatry 1993; 50: 457–65PubMedCrossRefGoogle Scholar
  24. 24.
    Silverstone T. Dopamine, mood and manic-depressive psychosis. In: Garattini S, editor. Depressive disorders. Stuttgart: Schattauer, 1978: 419–30Google Scholar
  25. 25.
    Silverstone T, McPherson H, Hunt N, et al. How effective is lithium in the prevention of relapse in bipolar disorder? A prospective naturalistic follow-up study. Aust N Z J Psychiatry 1998; 32(1): 61–6PubMedCrossRefGoogle Scholar
  26. 26.
    Goldberg JF, Harrow M, Grossman LS. Recurrent affective syndromes bipolar and unipolar mood disorders at follow-up. Br J Psychiatry 1995; 166: 382–5PubMedCrossRefGoogle Scholar
  27. 27.
    Schou M. Lithium prophylaxis: about ‘naturalistic’ or ‘clinical practice’ studies. Lithium 1993; 4: 77–81Google Scholar
  28. 28.
    Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder. Am J Psychiatry 1998; 155: 30–5PubMedGoogle Scholar
  29. 29.
    Moncrieff J. Lithium revisited: a re-examination of the placebo controlled trials of lithium prophylaxis in manic-depressivedisorder. Br J Psychiatry 1995; 167: 569–74PubMedCrossRefGoogle Scholar
  30. 30.
    Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48(12): 1082–8PubMedCrossRefGoogle Scholar
  31. 31.
    Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489–93PubMedCrossRefGoogle Scholar
  32. 32.
    Bowden CL. Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. J Clin Psychiatry 1998; 59 Suppl. 6: 13–9Google Scholar
  33. 33.
    Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. J Clin Psychiatry 1999; 60 Suppl. 5: 5–13; discussion 14-5Google Scholar
  34. 34.
    Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229–33PubMedCrossRefGoogle Scholar
  35. 35.
    Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord 1990; 18(4): 259–66PubMedCrossRefGoogle Scholar
  36. 36.
    Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986; 10(2): 115–25PubMedCrossRefGoogle Scholar
  37. 37.
    Grof P, Alsa M, Grof E, et al. The challenge of predicting response to stabilising lithium treatment. Br J Psychiatry 1993; 163 Suppl. 21: 16–9Google Scholar
  38. 38.
    Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57(5): 481–9Google Scholar
  39. 39.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  40. 40.
    Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57(2): 187–90PubMedCrossRefGoogle Scholar
  41. 41.
    Potter WZ, Ozcan ME. Methodological considerations for the development of new treatments for bipolar disorder. Aust N Z JPsychiatry 1999; 33 Suppl. : S84–98CrossRefGoogle Scholar
  42. 42.
    Vestergaard P, Wentzer Licht R, Brodersen A, et al. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels [see comments]. Acta Psychiatr Scand 1998; 98(4): 310–5PubMedCrossRefGoogle Scholar
  43. 43.
    Schumann C, Lenz G, Berghofer A, et al. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res 1999; 89(3): 247–57PubMedCrossRefGoogle Scholar
  44. 44.
    Nilsson A, Axelsson R. Factors associated with discontinuation of long-term lithium treatment. Acta Psychiatr Scand 1989; 80(3): 221–30PubMedCrossRefGoogle Scholar
  45. 45.
    Jamison K, Gerner R, Goodwin F. Patient and physician attitudes towards lithium: relationship to compliance. Arch Gen Psychiatry 1979; 36 (8 Spec No): 866–9PubMedCrossRefGoogle Scholar
  46. 46.
    Weiss RD, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998; 59(4): 172–4PubMedCrossRefGoogle Scholar
  47. 47.
    Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance [see comments]. J Clin Psychiatry 1989; 50(4): 127–31PubMedGoogle Scholar
  48. 48.
    Bech P, Vendsborg PB, Rafaelsen OJ. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatr Scand 1976; 53(1): 70–81PubMedCrossRefGoogle Scholar
  49. 49.
    Faedda GL, Tondo L, Baldessarini R, et al. Outcome after rapid vs gradual discontinuation of lithium in bipolar disorders. Arch Gen Psychiatry 1993; 50: 448–55PubMedCrossRefGoogle Scholar
  50. 50.
    Baldessarini R, Tondo L, Viguera AC. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord 1999; 1: 17–24PubMedCrossRefGoogle Scholar
  51. 51.
    Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder [editorial]. Br J Psychiatry 1994; 164(2): 149–52Google Scholar
  52. 52.
    Post RM, Leverich GS, Altshuler L, et al. Lithium-discontinuationinduced refractoriness: preliminary observations [see comments]. Am J Psychiatry 1992; 149(12): 1727–9PubMedGoogle Scholar
  53. 53.
    Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry 1995; 152: 1810–1PubMedGoogle Scholar
  54. 54.
    Tondo L, Baldessarini RJ, Floris G, et al. Effectiveness of retreating with lithium after its discontinuation in bipolar I and II disorders. Am J Psychiatry 1997; 154: 548–50PubMedGoogle Scholar
  55. 55.
    Berghofer A, Kossmann B, Muller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand 1996; 93(5): 349–54PubMedCrossRefGoogle Scholar
  56. 56.
    Coryell W, Solomon D, Leon AC, et al. Lithium discontinuation and subsequent effectiveness [see comments]. Am J Psychiatry 1998; 155(7): 895–8PubMedGoogle Scholar
  57. 57.
    Kleindienst N, Greil W, Ruger B, et al. The prophylactic efficacy of lithium—transient or persistent? Eur Arch Psychiatry Clin Neurosci 1999; 249(3): 144–9PubMedCrossRefGoogle Scholar
  58. 58.
    Norton B, Whalley LJ. Mortality of a lithium-treated population. Br J Psychiatry 1984; 145: 277–82PubMedCrossRefGoogle Scholar
  59. 59.
    Vestergaard P. Clinically important side effects of long-term lithium treatment: a review. Acta Psychiatr Scand Suppl 1983; 305: 1–36PubMedGoogle Scholar
  60. 60.
    Ahrens B, Muller-Oerlinghausen B, Schou M, et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995; 33(2): 67–75PubMedCrossRefGoogle Scholar
  61. 61.
    Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manicdepressive disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 77–84; discussion 111-6Google Scholar
  62. 62.
    Nilsson A. Lithium therapy and suicide risk. J Clin Psychiatry 1999; 60 Suppl. 2: 85–8; discussion 111-6Google Scholar
  63. 63.
    Peet M, Harvey NS. Lithium maintenance: 1. A standard education programme for patients [see comments].Br J Psychiatry 1991; 158: 197–200PubMedCrossRefGoogle Scholar
  64. 64.
    Scott J. Psychotherapy for bipolar disorder. Br J Psychiatry 1995; 167(5): 581–8PubMedCrossRefGoogle Scholar
  65. 65.
    Colom F, Vieta E, Martinez A, et al. What is the role of psychotherapy in the treatment of bipolar disorder? Psychother Psychosom 1998; 67(1): 3–9PubMedCrossRefGoogle Scholar
  66. 66.
    Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20(3): 231–43PubMedCrossRefGoogle Scholar
  67. 67.
    Bauer M, Blumentritt H, Schlattmann P, et al. The prevalence of goitre in lithium-treated patients: a controlled ultrasonographic study [abstract]. Bipolar Disord 1999; 1 Suppl. 1: 24Google Scholar
  68. 68.
    Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol 1990; 5(3): 217–25PubMedCrossRefGoogle Scholar
  69. 69.
    Elmslie JL, Silverstone JT, Mann JI, et al. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61(3): 179–84PubMedCrossRefGoogle Scholar
  70. 70.
    Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53(2): 139–47PubMedCrossRefGoogle Scholar
  71. 71.
    Jerram TC, McDonald R. Plasma lithium control with particular reference to minimum effective levels. In: Johnson FN, Johnson S, editors. Lithium in medical practice. Lancaster: MTP Press, 1978: 407–13Google Scholar
  72. 72.
    Coppen A, Abou-Saleh MT. Lithium therapy: from clinical trials to practical management. Acta Psychiatr Scand 1988; 78: 744–62CrossRefGoogle Scholar
  73. 73.
    Maj M, Starace F, Nolfe G, et al. Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry 1986; 19(6): 420–3PubMedCrossRefGoogle Scholar
  74. 74.
    Rosenbaum JF, Sachs GS, Lafer B, et al. High rates of relapse in bipolar patients abruptly changed from standard to low plasma lithium levels in a double-blind controlled trial. Proceedings of the Annual Meeting of the New Clinical Drug Evaluations Unit 1992Google Scholar
  75. 75.
    Silverstone T, Romans S. Long term management of bipolar disorder. Drugs 1996; 51: 367–82PubMedCrossRefGoogle Scholar
  76. 76.
    Sachs G, Renshaw P, Lafer B. Variability of brain lithium levels during maintenance treatment: a magnetic resonance spectroscopic study. Biol Psychiatry 1995; 38: 422–8PubMedCrossRefGoogle Scholar
  77. 77.
    Zalzstein E, Koren G, Einarson T, et al. A case-control study on the association between first trimester exposure to lithium and Ebstein’s anomaly. Am J Cardiol 1990; 65: 817–8PubMedCrossRefGoogle Scholar
  78. 78.
    Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146–50PubMedCrossRefGoogle Scholar
  79. 79.
    Llewellyn A, Stowe ZN, Strader JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Psychiatry 1998; 59 Suppl. 6: 57–64Google Scholar
  80. 80.
    Jacobson S, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530–3PubMedCrossRefGoogle Scholar
  81. 81.
    Hunt N, Silverstone T. Does puerperal illness distinguish a subgroup of bipolar patients? J Affect Disord 1995; 34(2): 101–7PubMedCrossRefGoogle Scholar
  82. 82.
    Stewart DE, Klompenauer JL, Kendell RE. Prophylactic lithium in puerperal psychosis. Br J Psychiatry 1991; 158: 393–7PubMedCrossRefGoogle Scholar
  83. 83.
    Austin M-P. Puerperal affective psychosis. Br J Psychiatry 1992; 161: 692–4PubMedCrossRefGoogle Scholar
  84. 84.
    Lambert PA, Carraz G, Borselli S, et al. Action neuropsychotrope d’un nouvel antiepileptique: le Depamide. Ann Med Psychol (Paris) 1966; 1: 707–10Google Scholar
  85. 85.
    Okuma T, Kishimoto A, Inoue K, et al. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr Neurol Jpn 1973; 27(4): 283–97Google Scholar
  86. 86.
    Mitchell PB. The place of anticonvulsants and other putative mood stabilisers in the treatment of bipolar disorder. Aust N Z J Psychiatry 1999; 33 Suppl. : S99–107PubMedCrossRefGoogle Scholar
  87. 87.
    Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983; 140(12): 1602–4PubMedGoogle Scholar
  88. 88.
    Kishimoto A, Ogura C, Hazama H, et al. Long-term prophylactic effects of carbamazepine in affective disorder. Br JPsychiatry 1983; 143: 327–31CrossRefGoogle Scholar
  89. 89.
    Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986; 47(10): 490–4PubMedGoogle Scholar
  90. 90.
    Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania [see comments]. Br J Psychiatry 1988; 153: 198–204PubMedCrossRefGoogle Scholar
  91. 91.
    Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85(2): 114–8PubMedCrossRefGoogle Scholar
  92. 92.
    Simhandl C, Denk E, Thau K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 1993; 28(4): 221–31PubMedCrossRefGoogle Scholar
  93. 93.
    Watkins SE, Callender K, Thomas DR, et al. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987; 150: 180–2PubMedCrossRefGoogle Scholar
  94. 94.
    Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br J Psychiatry 1995; 166(3): 378–81PubMedCrossRefGoogle Scholar
  95. 95.
    Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58(11): 470–8PubMedCrossRefGoogle Scholar
  96. 96.
    Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18(6): 455–60PubMedCrossRefGoogle Scholar
  97. 97.
    Joyce PR. Carbamazepine in rapid cycling bipolar affective disorder. Int Clin Psychopharmacol 1988; 3(2): 123–9PubMedCrossRefGoogle Scholar
  98. 98.
    Bocchetta A, Chillotti C, Severino G, et al. Carbamazepine augmentation in lithium-refractory bipolar patients: a prospective study on long-term effectiveness. J Clin Psychopharmacol 1997; 17: 92–6PubMedCrossRefGoogle Scholar
  99. 99.
    Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr Scand 1991; 83(6): 456–9PubMedCrossRefGoogle Scholar
  100. 100.
    Tohen M, Castillo J, Baldessarini RJ, et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am JPsychiatry 1995; 152(3): 413–8Google Scholar
  101. 101.
    Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. Part I. J Clin Psychopharmacol 1991; 11(3): 198–203Google Scholar
  102. 102.
    Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674–7PubMedCrossRefGoogle Scholar
  103. 103.
    Pope Jr HG, McElroy SL, Keck Jr PE, et al. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991; 48(1): 62–8CrossRefGoogle Scholar
  104. 104.
    Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271(12): 918–24PubMedCrossRefGoogle Scholar
  105. 105.
    McElroy SL, Keck Jr PE, Pope Jr HG, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992; 121 Suppl. : 42–52SCrossRefGoogle Scholar
  106. 106.
    Bowden CL, Swann AC, Calabrese JR, et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproexlithium-placebo study. Psychopharmacol Bull 1997; 33(4): 693–9PubMedGoogle Scholar
  107. 107.
    McElroy SL, Keck Jr PE, Pope Jr HG, et al. Valproate in the treatment of rapid-cycling bipolar disorder [see comments]. J Clin Psychopharmacol 1988; 8(4): 275–9PubMedCrossRefGoogle Scholar
  108. 108.
    Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990; 147(4): 431–4PubMedGoogle Scholar
  109. 109.
    Mitchell P, Withers K, Jacobs G, et al. Combining lithium and sodium valproate for bipolar disorder. Aust N Z J Psychiatry 1994; 28(1): 141–3PubMedCrossRefGoogle Scholar
  110. 110.
    Solomon DA, Ryan CE, Keitner GI, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58(3): 95–9PubMedCrossRefGoogle Scholar
  111. 111.
    Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy [see comments]. Am J Psychiatry 1998; 155(1): 12–21PubMedGoogle Scholar
  112. 112.
    Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder [see comments]. Am J Psychiatry 1997; 154(10): 1456–8PubMedGoogle Scholar
  113. 113.
    Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993; 69 (3 Spec No): 288–91PubMedCrossRefGoogle Scholar
  114. 114.
    Suppes T, Brown ES, McElroy SL, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 53(1): 95–8PubMedCrossRefGoogle Scholar
  115. 115.
    Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156(7): 1019–23PubMedGoogle Scholar
  116. 116.
    Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol 1999; 9 Suppl 4: S119–23PubMedCrossRefGoogle Scholar
  117. 117.
    Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60(2): 79–88CrossRefGoogle Scholar
  118. 118.
    Ascher J, Cookson J, Huffman R, et al. Profile of antidepressant activity of lamotrigine in bipolar depression: results from a double-blind, placebo-controlled study [abstract]. Bipolar Disord 1999; 1 Suppl. 1: 23Google Scholar
  119. 119.
    Bryant-Comstock L, Chang C, Phillips S. Quality of life improvement in bipolar patients treated with lamotrigine. Bipolar Disord 1999; 1 Suppl. 1: 25–6CrossRefGoogle Scholar
  120. 120.
    Knoll J, Stegman K, Suppes T. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. J Affect Disord 1998; 49(3): 229–33PubMedCrossRefGoogle Scholar
  121. 121.
    Cabras PL, Hardoy MJ, Hardoy MC. Clinical Experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatry 1999; 60: 245–8PubMedCrossRefGoogle Scholar
  122. 122.
    Perugi G, Toni C, Ruffolo G, et al. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiatry 1999; 32(4): 136–41PubMedCrossRefGoogle Scholar
  123. 123.
    Young LT, Robb JC, Hasey GM, et al. Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 1999; 55(1): 73–7PubMedCrossRefGoogle Scholar
  124. 124.
    Ande AC. Combination treatment in bipolar disorder [abstract]. Bipolar Disord 1999; 1 Suppl. 1: 48Google Scholar
  125. 125.
    Shaffer CB, Shaffer LC. Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment [abstract]. Bipolar Disord 1999; 1 Suppl. 1: 48Google Scholar
  126. 126.
    Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50(2–3): 245–51PubMedCrossRefGoogle Scholar
  127. 127.
    Gordon A, Price LH. Mood stabilization and weight loss with topiramate [letter]. Am J Psychiatry 1999; 156(6): 968–9PubMedGoogle Scholar
  128. 128.
    Normann C, Langosch J, Schaerer LO, et al. Treatment of acute mania with topiramate [letter]. Am J Psychiatry 1999; 156(12): 2014PubMedGoogle Scholar
  129. 129.
    Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60(11): 759–62PubMedCrossRefGoogle Scholar
  130. 130.
    Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder. Am J Psychiatry 1999; 156: 2014–5PubMedGoogle Scholar
  131. 131.
    Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996; 57 Suppl. 9: 49–52Google Scholar
  132. 132.
    Keck Jr PE, McElroy SL, Strakowski SM, et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 Suppl. 4: 33–8Google Scholar
  133. 133.
    Yassa R, Ghadirian AM, Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry 1983; 44(11): 410–2PubMedGoogle Scholar
  134. 134.
    Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986; 43(4): 342–6PubMedCrossRefGoogle Scholar
  135. 135.
    Hunt N, Silverstone T. Tardive dyskinesia in bipolar affective disorder: a catchment area study. Int Clin Psychopharmacol 1991; 6(1): 45–50PubMedCrossRefGoogle Scholar
  136. 136.
    White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993; 8(2): 119–22PubMedCrossRefGoogle Scholar
  137. 137.
    Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994; 165(6): 827–9PubMedCrossRefGoogle Scholar
  138. 138.
    Tohen M, Zarate Jr CA, Centorrino F, et al. Risperidone in the treatment of mania. J Clin Psychiatry 1996; 57(6): 249–53PubMedGoogle Scholar
  139. 139.
    Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21(3): 176–80PubMedGoogle Scholar
  140. 140.
    Ghaemi SN, Sachs GS. Long-term risperidone treatment in bipolar disorder: 6-month follow up. Int Clin Psychopharmacol 1997; 12(6): 333–8PubMedCrossRefGoogle Scholar
  141. 141.
    Dunayevich E, McElroy SL. Atypical antipsychotics in the treatment of bipolar disorder: pharmacological and clinical effects. CNS Drugs 2000; 13(6): 433–41CrossRefGoogle Scholar
  142. 142.
    Banov MD, Zarate Jr CA, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55(7): 295–300PubMedGoogle Scholar
  143. 143.
    Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153(6): 759–64PubMedGoogle Scholar
  144. 144.
    Zarate Jr CA, Tohen M, Banov MD, et al. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56(3): 108–12PubMedGoogle Scholar
  145. 145.
    Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1 -year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156(8): 1164–9PubMedGoogle Scholar
  146. 146.
    McElroy SL, Frye M, Denicoff K, et al. Olanzapine in treatmentresistant bipolar disorder. J Affect Disord 1998; 49(2): 119–22PubMedCrossRefGoogle Scholar
  147. 147.
    Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156(5): 702-9Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Department of Psychological Medicine, Dunedin School of MedicineUniversity of OtagoDunedinNew Zealand

Personalised recommendations